Skip to main content
. 2023 Apr 17;133(8):e157937. doi: 10.1172/JCI157937

Figure 4. Therapeutic effects against liver metastasis by bacteria-mediated disruption of c-Maf/MafB in KCs.

Figure 4

(A) Representative images showing ClearColi captured by KCs at 1 hour after infection in tumor-bearing mice. Scale bars: 200 μm. Original magnification, zoomed images: × 5.6. (B) Mice were treated with E. coli–vector or E. coli–sgMafb/Maf at day 7 after B16F10 tumor inoculation and were harvested at day 15 as illustrated. (C) Liver weight and tumor area on the surface of the liver were quantified. n = 8–9 mice per group pooled from 2 experiments. (D) Treatment of late-stage B16F10 melanoma liver metastasis as depicted. (E) Liver weights at day 19 were measured. (F) Mouse survival was monitored. Pooled data of 22–25 mice per group from 4 independent experiments. (G–I) Treatment of late-stage MC38 liver metastasis. Pooled data of 8–11 mice per group from 2 independent experiments. (J–K) Treatment of late-stage LLC liver metastasis. Pooled data of 8–9 mice per group from 2 independent experiments. Scale bars: 1 cm (B, D, G, and J). For E and H, mice that reached the end point of the experiment were euthanized before harvest and were excluded from liver weight analysis. Arrows in F and I indicate time points of bacterial treatment. Data are represented as mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001, unpaired Student’s t test (C, E, H and K); 2-sided log-rank test (F and I).